| 1 |
Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
Evan S. Dellon et al. · New England Journal of Medicine
Open access |
21 Oct 2020 |
269 |
| 2 |
Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody
Simon Gebremeskel, Julia Schanin, Krysta Mila Coyle et al. · Frontiers in Immunology
Open access |
10 Mar 2021 |
111 |
| 3 |
AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice
Bradford A. Youngblood, Emily C. Brock, John W. Leung et al. · International Archives of Allergy and Immunology
Open access |
2019 |
111 |
| 4 |
Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis
Bradford A. Youngblood, Emily C. Brock, John W. Leung et al. · JCI Insight
Open access |
29 Aug 2019 |
106 |
| 5 |
An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria
Sabine Altrichter, Petra Staubach, MUHAMMAD N PASHA et al. · Journal of Allergy and Clinical Immunology
Open access |
23 Dec 2021 |
104 |
| 6 |
Humanized mouse model of mast cell–mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis
Paul J. Bryce, Rustom Falahati, Laurie L. Kenney et al. · Journal of Allergy and Clinical Immunology
Open access |
7 Apr 2016 |
104 |
| 7 |
Discovery, Function, and Therapeutic Targeting of Siglec-8
Bradford A. Youngblood, John W. Leung, Rustom Falahati et al. · Cells
Open access |
24 Dec 2020 |
90 |
| 8 |
Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model
Jacqueline McBride, Jeremy J. Lim, Tracy Burgess et al. · Antimicrobial Agents and Chemotherapy
Open access |
15 Aug 2017 |
79 |
| 9 |
A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation
Julia Schanin, Simon Gebremeskel, Wouter Korver et al. · Mucosal Immunology
Open access |
19 Aug 2020 |
77 |
| 10 |
Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study
Mirna Chehade, Amol P. Kamboj, Dan Atkins et al. · The Journal of Allergy and Clinical Immunology In Practice
Open access |
12 Jan 2021 |
76 |
| 11 |
Mast cell activation is associated with post‐acute COVID‐19 syndrome
Joshua B. Wechsler, Melina Butuci, Alan Wong et al. · Allergy
Open access |
25 Nov 2021 |
68 |
| 12 |
Eosinophil and mast cell Siglecs: From biology to drug target
Jeremy A. O’Sullivan, Alan T. Chang, Bradford A. Youngblood et al. · Journal of Leukocyte Biology
Open access |
22 Jan 2020 |
67 |
| 13 |
Mast Cell and Eosinophil Counts in Gastric and Duodenal Biopsy Specimens From Patients With and Without Eosinophilic Gastroenteritis
Craig C. Reed, Robert M. Genta, Bradford A. Youngblood et al. · Clinical Gastroenterology and Hepatology
Open access |
12 Aug 2020 |
61 |
| 14 |
Sialic acid–binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies
Fanny Legrand, Yun Cao, Joshua B. Wechsler et al. · Journal of Allergy and Clinical Immunology
Open access |
10 Dec 2018 |
60 |
| 15 |
Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab
Evan S. Dellon, Nirmala Gonsalves, Marc E. Rothenberg et al. · Clinical Gastroenterology and Hepatology
Open access |
2 Jun 2021 |
59 |
| 16 |
Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell‐mediated diseases
Martin Metz, Pavel Kolkhir, Sabine Altrichter et al. · Allergy
Open access |
22 Aug 2023 |
52 |
| 17 |
Lirentelimab for severe and chronic forms of allergic conjunctivitis
Stephen D. Anesi, Joseph Tauber, Quan Dong Nguyen et al. · Journal of Allergy and Clinical Immunology
Open access |
4 Apr 2022 |
49 |
| 18 |
An anti‐siglec‐8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells
Sheena C. Kerr, Jeanmarie R. Gonzalez, Julia Schanin et al. · Clinical & Experimental Allergy
Open access |
16 Jun 2020 |
45 |
| 19 |
The Inhibitory Receptor Siglec-8 Interacts With FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation
Wouter Korver, Alan Wong, Simon Gebremeskel et al. · Frontiers in Immunology
Open access |
28 Jan 2022 |
40 |
| 20 |
Critical considerations in the formulation development of parenteral biologic drugs
Bilikallahalli K. Muralidhara, Marcus Thien Chong Wong · Drug Discovery Today
|
8 Jan 2020 |
40 |
| 21 |
Functional and Phenotypic Characterization of Siglec-6 on Human Mast Cells
Piper A. Robida, Clayton H. Rische, Netali Ben-Baruch Morgenstern et al. · Cells
Open access |
28 Mar 2022 |
33 |
| 22 |
Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial
Frank Siebenhaar, Sabine Altrichter, Hanna Bonnekoh et al. · British Journal of Dermatology
|
8 Jun 2023 |
28 |
| 23 |
A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Phase 1 Study of AK002, a Novel Siglec-8 Selective Monoclonal Antibody, in Healthy Subjects
Henrik Sandvad Rasmussen, Alan T. Chang, Nenad Tomašević et al. · Journal of Allergy and Clinical Immunology
|
Feb 2018 |
26 |
| 24 |
Siglecs in allergy and asthma
Bruce Scott Bochner, Jeremy A. O’Sullivan, Alan T. Chang et al. · Molecular Aspects of Medicine
Open access |
11 Jul 2022 |
25 |
| 25 |
Siglecs as potential targets of therapy in human mast cell- and/or eosinophil-associated diseases
Jeremy A. O’Sullivan, Bradford A. Youngblood, Robert P. Schleimer et al. · Seminars in Immunology
Open access |
4 Jul 2023 |
23 |
| 26 |
Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells
Julia Schanin, Wouter Korver, Emily C. Brock et al. · Communications Biology
Open access |
11 Nov 2022 |
23 |
| 27 |
High Discovery Rate of Duodenal and Gastric Eosinophilia in Patients With Unexplained Moderate–Severe Abdominal Symptoms: A Prospective US Multisite Study
Nicholas Joseph Talley, Kathryn A. Peterson, Robert M. Genta et al. · Gastroenterology
Open access |
24 Dec 2022 |
22 |
| 28 |
The Number of MRGPRX2-Expressing Cells Is Increased in Skin Lesions of Patients With Indolent Systemic Mastocytosis, But Is Not Linked to Symptom Severity
Polina Pyatilova, Tameem Ashry, Yanyan Luo et al. · Frontiers in Immunology
Open access |
26 Jul 2022 |
18 |
| 29 |
Rhinology Future Debates, an EUFOREA Report
Wytske Johanna Fokkens, Claus Bachert, Manuel S Bernal‐Sprekelsen et al. · Rhinology Journal
|
2017 |
18 |
| 30 |
Detecting Changes in Mast Cell Numbers Versus Activation in Human Disease: A Roadblock for Current Biomarkers?
Cem Akin, Frank Siebenhaar, Joshua B. Wechsler et al. · The Journal of Allergy and Clinical Immunology In Practice
Open access |
11 Mar 2024 |
15 |
| 31 |
Determination of Optimal Eosinophil Thresholds for Diagnosis of Eosinophilic Gastritis and Duodenitis: A Pooled Analysis of 4 Prospective Studies
Evan S. Dellon, Enoch B. Bortey, Alan T. Chang et al. · Clinical and Translational Gastroenterology
Open access |
20 Oct 2023 |
14 |
| 32 |
Gastroenterology Practice Patterns Contribute to Missed Diagnoses of Eosinophilic Gastritis and Duodenitis
Mirna Chehade, Jingwen Tan, Lauren Gehman · Gastro Hep Advances
Open access |
25 Nov 2022 |
10 |
| 33 |
Regulation of mast cells by overlapping but distinct protein interactions of Siglec‐6 and Siglec‐8
Wouter Korver, Zachary L. Benet, Alan Wong et al. · Allergy
Open access |
7 Jan 2024 |
9 |
| 34 |
AK002, an Anti-Siglec-8 Antibody, Depletes Tissue Eosinophils and Improves Dysphagia Symptoms in Patients with Eosinophilic Esophagitis
Ikuo Hirano, Kathryn A. Peterson, Joseph A. Murray et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2020 |
9 |
| 35 |
Clinical Activity of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Treatment-Refractory Chronic Urticaria
Sabine Altrichter, Petra Staubach, MUHAMMAD N PASHA et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2020 |
7 |
| 36 |
The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States
Michael E. Woolley, Erin E. Cook, Fan Mu et al. · Advances in Therapy
Open access |
10 Jun 2022 |
6 |
| 37 |
Phase 1b Study of AK002, an Anti-Siglec-8 Monoclonal Antibody, in Patients with Severe Allergic Conjunctivitis (KRONOS Study)
H Levine, Joseph Tauber, Quan Nguyen et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2020 |
6 |
| 38 |
Atopic Dermatitis Skin Biopsies Have High Numbers of Activated Mast Cells that Are Inhibited by AK002 after Stimulation Ex Vivo
Brad L. Youngblood, Julia Schanin, Nenad Tomašević et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2020 |
6 |
| 39 |
An Agonistic Monoclonal Antibody Against Siglec-6 Broadly Inhibits Mast Cell Activation in Transgenic Mice
Zachary L. Benet, Thuy Mai Luu, Emily C. Brock et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2023 |
5 |
| 40 |
Mast Cells are Locally Activated and Respond to MRGPRX2 Stimulation in Atopic Dermatitis Ex Vivo Skin Biopsies
Melina Butuci, Zachary L. Benet, Alan Wong et al. · Journal of Allergy and Clinical Immunology
|
Feb 2022 |
5 |
| 41 |
287 Targeting the inhibitory receptor Siglec-8 on mast cells represents an attractive approach to reduce MRGPRX2-mediated mast cell activation
Zachary L. Benet, Alan Wong, Julia Schanin et al. · British Journal of Dermatology
|
25 Jan 2023 |
4 |
| 42 |
A Recombinant Antibody to Siglec-8 Shows Selective ADCC Activity Against Mast Cells from Systemic Mastocytosis Patients
Rustom Falahati, Jessica M. Bright, Alejandro Dorenbaum et al. · Blood
|
3 Dec 2015 |
4 |
| 43 |
CSTB and FABP5 Serum mRNA Differentiate Histologically Active and Inactive Patients With Eosinophilic Esophagitis
Jared A. Sninsky, Siyao Liu, Swathi Eluri et al. · Gastro Hep Advances
Open access |
2 Sep 2023 |
3 |
| 44 |
MRGPRX2-Mediated Mast Cell Activation is a Shared Pathogenic Mechanism in Atopic Dermatitis and Prurigo Nodularis Patients that can be Therapeutically Targeted via Siglecs
Zachary L. Benet, Thuy T. Luu, Emily C. Brock et al. · Journal of Allergy and Clinical Immunology
|
Feb 2024 |
2 |
| 45 |
A Longitudinal, Population-Based Study of the Difficult Journey to Diagnosis Endured by Patients with Eosinophilic Gastritis and Eosinophilic Gastroenteritis
Mirna Chehade, Lauren Gehman, Amol P. Kamboj et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2020 |
2 |
| 46 |
EoE Biopsies have Elevated and Activated Mast Cells that Produce Cytokines and Chemokines that Drive Disease Pathogenesis
Melina Butuci, Emily C. Brock, Julia Schanin et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2020 |
1 |
| 47 |
1246 Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Endure a Lengthy Path to Diagnosis and Experience Persistent Symptoms After Diagnosis
Mirna Chehade, Lauren Gehman, Henrik Sandvad Rasmussen · The American Journal of Gastroenterology
|
Oct 2019 |
1 |
| 48 |
1247 Development of a Patient Reported Outcome (PRO) Questionnaire to Assess the Symptoms of Eosinophilic Gastritis and Gastroenteritis (EG/EGE-SQ©)
Ikuo Hirano, Evan S. Dellon, Joseph A. Murray et al. · The American Journal of Gastroenterology
|
Oct 2019 |
1 |
| 49 |
484 - Phase 2 trial in progress - lirentelimab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments
Cristian Rodríguez, Anesa Moyer, Alan T. Chang et al. · British Journal of Dermatology
|
Feb 2024 |
0 |
| 50 |
365 Phase 2 trial in progress—lirentelimab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments
Cristian Rodríguez, Anesa Moyer, Alan T. Chang et al. · British Journal of Dermatology
|
Jun 2023 |
0 |